Rigel Pharmaceuticals (RIGL) Receivables - Net (2013 - 2026)

Rigel Pharmaceuticals' Receivables - Net history runs 13 years deep, the most recent figure standing at $49.9 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 1564.83% year-over-year to $49.9 million; the TTM figure through Mar 2026 stood at $49.9 million (up 1564.83% YoY), while the FY2025 annual figure was $51.8 million, up 24.39% from the prior year.
• Receivables - Net for Q1 2026 stood at $49.9 million, down from $51.8 million in the prior quarter.
• The five-year high for Receivables - Net was $51.8 million in Q4 2025, with the low at $3.0 million in Q1 2025.
• The 5-year median for Receivables - Net is $28.9 million (2024), against an average of $28.9 million.
• The sharpest annual moves came in 2022 and 2026: Receivables - Net sank 89.28% in 2022, then jumped 1564.83% in 2026.
• Rigel Pharmaceuticals' Receivables - Net stood at $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then surged by 36.22% to $41.6 million in 2024, then climbed by 24.39% to $51.8 million in 2025, then slipped by 3.51% to $49.9 million in 2026.
• Business Quant data shows RIGL's Receivables - Net at $49.9 million in Q1 2026, $51.8 million in Q4 2025, and $45.9 million in Q3 2025.